Table 2. Proportional hazards models depicting the interaction between rs10916264 genotype (additive model) and TP53 immunohistochemistry in ER-positive cases, and between rs798755 genotype (recessive model) and adjuvant anthracycline chemotherapy.

	rs10916264:TP53 IHC a				rs798755:Anthracycline b
Model without interaction term	HR (95% C.I.)		p-value		HR (95% C.I.)		p-value
SNP	0.93 (0.82 – 1.06)		0.22914		0.95 (0.74 – 1.22)		0.6970
TP53 IHC	1.56 (1.23 – 2.00)		0.00033		-		-
Anthracycline treatment	-		-		1.68 (1.47 – 1.92)		1.5 × 10-14
Age at diagnosis	1.05 (1.04 – 1.06)		< 10-16		1.04 (1.04 – 1.05)		< 10-16
Model with interaction term	HR (95% C.I.)		p-value		HR (95% C.I.)		p-value
SNP	0.83 (0.73 – 0.96)		0.0093		0.72 (0.52 – 0.98)		0.0352
TP53 IHC	0.83 (0.54 – 1.25)		0.3602		-		-
Anthracycline treatment	-		-		1.61 (1.40 – 1.84)		6.9 × 10-12
Age at diagnosis	1.05 (1.04 – 1.06)		< 10-16		1.04 (1.04 – 1.05)		< 10-16
SNP:TP53 interaction	2.06 (1.47 – 2.91)		3.3 × 10-5		-		-
SNP:Anthracycline interaction	-		-		2.99 (1.78 – 5.01)		3.5 × 10-5
Likelihood-ratio test for interaction	p(interaction) = 3.44 × 10-5				p(interaction) = 9.57 × 10-5
Adjusted for prognostic factors	HR (95% C.I.)		p-value		HR (95% C.I.)		p-value
SNP	0.87 (0.75 – 1.01)		0.0712		0.92 (0.63 – 1.36)		0.6883
TP53 IHC	0.77 (0.49 – 1.23)		0.2748		-		-
Anthracycline treatment	-		-		0.98 (0.80 – 1.20)		0.8487
Age at diagnosis	1.06 (1.05 – 1.07)		< 10-16		1.05 (1.04 – 1.06)		< 10-16
Estrogen receptor (ER) status	-		-		0.73 (0.61 – 0.86)		2.5 × 10-5
Grade	1.39 (1.19 – 1.62)		3.6 × 10-5		1.40 (1.26 – 1.55)		5.3 × 10-10
Tumor size (mm)	1.01 (1.01 – 1.02)		3.2 × 10-5		1.01 (1.01 – 1.02)		1.6 × 10-14
Node status	1.78 (1.44 – 2.19)		7.2 × 10-8		1.88 (1.63 – 2.17)		< 10-16
SNP:TP53 interaction	1.69 (1.16 – 2.46)		0.0047		-		-
SNP:Anthracycline interaction	-		-		2.30 (1.08 – 4.86)		0.0299

^a Additive model, among ER-positive cases only

^b Recessive model, all cases